Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)

NCT01190930 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT01190930
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01190930 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
August 11, 2010
Completion date
March 31, 2026
Enrollment
9,350 (actual)
Sites
243

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, adult b lymphoblastic lymphoma, ann arbor stage i b lymphoblastic lymphoma, ann arbor stage ii b lymphoblastic lymphoma, childhood b acute lymphoblastic leukemia, childhood b acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2); bcr-abl1, childhood b lymphoblastic lymphoma, down syndrome, hypodiploid b acute lymphoblastic leukemia, philadelphia chromosome positive